JLE

Médecine thérapeutique

MENU

Maladie de Buerger : à propos d’un cas Volume 24, numéro 2, Mars-Avril 2018

  • [1] Olin J.W. Thromboangiitis obliterans (Buerger's disease). N Eng J Med. 2000;343:864-869.
  • [2] Puéchal X., Fissinger J.-N. Thromboangiitis obliterans or Buerger's disease challenges for the rheumatologist. Rheumatol Oxf Engl. 2007;46:192-199.
  • [3] Reny J.L., Cabane J. Buerger's disease or thromboangiitis obliterans. Rev Med Interne. 1998;19:34-43.
  • [4] Cooper L.T., Tse T.S., Mikhail M.A., McBane R.D., Stanson A.W., Ballman K.V. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger'sdisease). J Am Coll Cardiol. 2004;44:2410-2411.
  • [5] Malecki R., Zdrojowy K., Adamiec R. Thromboangiitis obliterans in the 21 century: a new face of disease. Atherosclerosis. 2009;206:328-334. st
  • [6] Olin J.W., Young J.R., Graor R.A., Ruschhaupt W.F., Bartholomew J.R. The changing clinical spectrum of throboangiitis obliterans (Buerger's disease). Circulation. 1990;82:3-8.
  • [7] Olin J.W., Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol. 2006;18:18-24.
  • [8] Avcu F., Akar E., Demirkiliç U., Yilmaz E., Akar N., Yalçin A. The role of prothrombotic mutations in patients with Buerger's disease. Thromb Res. 2000;100:143-147.
  • [9] Brodmann M., Renner W., Stark G. Prothrombotic risk factors in patients with thromboangiitis obliterans. Throm Res. 2000;99:483-486.
  • [10] Joviliano E.E., Dellalibera-Joviliano R., Dalio M., Evora P.R., Piccinato C.E. Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans-current practices. Int J Angiol. 2009;18:119.
  • [11] Fiessinger J.N., Schäfer M. Trial of iloprost aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet. 1990;335:555-557. versus
  • [12] Bozkurt A.K., Cengiz K., Caner A. A stable prostacyclin analogue (Iloprost) in the treatment of Buerger's Disease: a prospective analysis of 150 patients. Ann Thorac Cardiovasc Surg. 2013;19:120-125.
  • [13] De Haro J., Acin F., Bleda S., Varela C., Esparza L. Treatment of thromboangiitis obliterans (Buerger's disease) with Bosantan. BMC Cardiovasc Disord. 2012;12:5.
  • [14] Bozkurt A.K., Köksal C., Demirbas M.Y. A randomized trial of intravenous Iloprost lumbar sympathectomy in management of Buerger's disease. Int Angiol J. 2006;25:162-168. versus
  • [15] Deffontis T., Kintega R., Jannot Martin, Nicoud P., Hanf W. Acute kidney injury in thromboangiitis obliterans disease. Nephrol Therap. 2017. (in Press)
  • [16] Adar R., Papa M.Z. The definition of buerger's disease. World J Surg. 1984;8:423.
  • [17] Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). Basic data underlaying clinical decision making in vascular surgery. Ann Vascul Surg 1991 ; 5 : 570-2.
  • [18] Papa M.Z., Rabi I., Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg. 1996;11:335-339.
  • [19] Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol. 1998;66:S243-245.
  • [20] Ohata T., Ishioashi H., Hosaka M. Clinical and social consequences of buerger disease. J Vasc Surg. 2004;39:176-180.
  • [21] Sasaki S., Sakuma M., Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol. 2000;75:175-181.
  • [22] Singh I., Ramteke V.K. The role of omental transfer in Buerger's disease. New delhi's experience. Aust NZ J Surg. 1996;66:372-376.